Akero Therapeutics, Inc.
South San Francisco, US · Founded 2017 · 2 known investors
Founders & leadership
AK
Aaron KantoffNamed on SEC filing
MI
Mark IwickiNamed on SEC filing
GW
Graham WalmsleyNamed on SEC filing
JY
Jonathan YoungNamed on SEC filing
AC
Andrew ChengNamed on SEC filing
Board
AR
Aaron RoystonBoard director
KB
Kevin BittermanBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$45.5M disclosed across 1 round · 2018
▶$45.5MraisedDec 2018 · 20 investors · Other Health CareRule 506(b)
▶$45.5MraisedDec 2018 · 20 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Aaron KantoffDirector
- Aaron RoystonDirector
- Mark IwickiDirector
- Graham WalmsleyDirector
- Jonathan YoungExecutive Officer
- Kevin BittermanDirector
- Andrew ChengExecutive Officer, Director
- Offering amount
- $45.5M
- Amount sold
- $45.5M
- First sale
- Dec 2018
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who are Akero Therapeutics, Inc.'s investors?
- Akero Therapeutics, Inc.'s investors include Atlas Venture, venBio Partners.
- How much funding has Akero Therapeutics, Inc. raised?
- Akero Therapeutics, Inc. has disclosed $45.5M raised across 1 round.
- Where is Akero Therapeutics, Inc. headquartered?
- Akero Therapeutics, Inc. is headquartered in South San Francisco, US.